Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $563.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target hoisted by Stifel Nicolaus from $500.00 to $563.00 in a research note published on Tuesday,Benzinga reports. They currently have a hold rating on the pharmaceutical company’s stock.

A number of other brokerages have also commented on VRTX. UBS Group raised their target price on shares of Vertex Pharmaceuticals from $585.00 to $615.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. TD Cowen lifted their price target on shares of Vertex Pharmaceuticals from $525.00 to $550.00 and gave the company a “buy” rating in a research note on Wednesday, September 23rd. Canaccord Genuity Group boosted their price target on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a report on Tuesday, August 4th. Daiwa Securities Group increased their price objective on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $542.50 on Tuesday. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The business’s fifty day simple moving average is $522.81 and its two-hundred day simple moving average is $481.42. Vertex Pharmaceuticals has a twelve month low of $406.67 and a twelve month high of $568.67. The firm has a market cap of $137.69 billion, a price-to-earnings ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. During the same quarter last year, the business posted $4.80 earnings per share. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. Analysts predict that Vertex Pharmaceuticals will post 16.50 earnings per share for the current year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several large investors have recently modified their holdings of VRTX. BlackRock Inc. acquired a new position in shares of Vertex Pharmaceuticals in the second quarter worth $11,975,849,000. State Street Corp increased its position in shares of Vertex Pharmaceuticals by 1.2% during the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after acquiring an additional 141,320 shares during the period. Wellington Management Group LLP raised its stake in shares of Vertex Pharmaceuticals by 1.1% in the second quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock valued at $1,613,209,000 after acquiring an additional 35,069 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Vertex Pharmaceuticals by 1.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock valued at $1,533,248,000 after acquiring an additional 29,287 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at $1,509,651,000. Institutional investors own 90.96% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.